Franklin Genomic Advancements Etf Three Year Return
| HELX Etf | USD 29.53 0.29 0.99% |
Franklin Genomic Advancements fundamentals help investors to digest information that contributes to Franklin Genomic's financial success or failures. It also enables traders to predict the movement of Franklin Etf. The fundamental analysis module provides a way to measure Franklin Genomic's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Franklin Genomic etf.
Franklin |
Franklin Genomic Advancements ETF Three Year Return Analysis
Franklin Genomic's Tree Year Return shows the total annualized return generated from holding a fund or ETFs for the last three years. The return measure includes capital appreciation, losses, dividends paid, and all capital gains distributions. This return indicator is considered by many investors to be solid measures of fund mid-term performance.
More About Three Year Return | All Equity Analysis
Three Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Current Franklin Genomic Three Year Return | (17.10) % |
Most of Franklin Genomic's fundamental indicators, such as Three Year Return, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Franklin Genomic Advancements is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although Three Year Fund Return indicator can give a sense of overall fund mid-term potential, it is recommended to compare fund performances against other similar funds, ETFs, or market benchmarks for the same 3 year interval.
| Competition |
Based on the latest financial disclosure, Franklin Genomic Advancements has a Three Year Return of -17.1%. This is much lower than that of the Franklin Templeton Investments family and significantly lower than that of the Health category. The three year return for all United States etfs is notably higher than that of the company.
Franklin Three Year Return Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Franklin Genomic's direct or indirect competition against its Three Year Return to detect undervalued stocks with similar characteristics or determine the etfs which would be a good addition to a portfolio. Peer analysis of Franklin Genomic could also be used in its relative valuation, which is a method of valuing Franklin Genomic by comparing valuation metrics of similar companies.Franklin Genomic is currently under evaluation in three year return as compared to similar ETFs.
Fund Asset Allocation for Franklin Genomic
The fund consists of 98.96% investments in stocks, with the rest of investments allocated between various types of exotic instruments.Asset allocation divides Franklin Genomic's investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
Franklin Fundamentals
| Beta | 1.14 | |||
| Total Asset | 10.39 M | |||
| One Year Return | 5.50 % | |||
| Three Year Return | (17.10) % | |||
| Net Asset | 10.39 M | |||
| Equity Positions Weight | 98.96 % |
About Franklin Genomic Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Franklin Genomic Advancements's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Franklin Genomic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Franklin Genomic Advancements based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Franklin Genomic Adv offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Franklin Genomic's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Franklin Genomic Advancements Etf. Outlined below are crucial reports that will aid in making a well-informed decision on Franklin Genomic Advancements Etf:Check out Franklin Genomic Piotroski F Score and Franklin Genomic Altman Z Score analysis. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
The market value of Franklin Genomic Adv is measured differently than its book value, which is the value of Franklin that is recorded on the company's balance sheet. Investors also form their own opinion of Franklin Genomic's value that differs from its market value or its book value, called intrinsic value, which is Franklin Genomic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Franklin Genomic's market value can be influenced by many factors that don't directly affect Franklin Genomic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Franklin Genomic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Franklin Genomic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Franklin Genomic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.